Arup Pramanik is a dynamic, results-oriented senior executive whose distinguished 25-year career has spanned continents, therapeutic areas, and healthcare ecosystems. A recognized leader in global pharmaceutical innovation, Arup has continuously delivered transformative outcomes across commercial strategy, market access, pricing, and digital health. Known for his rare ability to unify scientific depth with commercial foresight, he has consistently championed patient-centered, evidence-based approaches that drive both enterprise growth and societal benefit. His motto, “Seeking evidence to find innovative solutions,” is not just a personal credo—it is the engine behind every initiative he leads.
Currently serving as Corporate Vice President, Market Access, Therapeutic Areas at Boehringer Ingelheim, Arup orchestrates cross-functional teams across global regions to deliver high-impact access and reimbursement strategies. Building and mentoring best in class teams. His leadership spans a broad portfolio of specialties, including immunology, rare diseases, oncology, and precision medicine. By integrating real-world evidence (RWE), artificial intelligence, and predictive analytics into traditional pharmaceutical pathways, Arup has helped reshape how therapies are commercialized and accessed in markets with varying levels of healthcare infrastructure and economic capacity.
Arup’s career trajectory reflects a deliberate and values-driven commitment to transforming healthcare access on a global scale. From his early days at Pfizer, where he supported clinical and commercial functions across Asia, to later spearheading strategic planning and market access initiatives at Novartis Oncology, his path has been one of continuous growth and vision. At Novartis, he was honored with multiple President’s Awards for pioneering innovative access models that blended data, stakeholder partnerships, and health economics—hallmarks of his leadership style.
His move to Shire Oncology (now part of Takeda) marked a pivotal expansion in Arup’s scope of influence. There, he led global access and advocacy efforts across the U.S., EMEA, Japan, and the Rest of the World, aligning cross-functional teams around value-based pricing and policy initiatives. He drove the launch of several major oncology assets, applying AI-powered forecasting to anticipate market dynamics and tailor pricing strategies accordingly. Arup’s deep appreciation for both patient needs and payer realities enabled him to achieve double- and triple-digit growth in some of the industry’s most competitive therapeutic areas.
At Indivior, Arup further honed his expertise in behavioral and mental health—sectors often underserved despite high unmet need. His strategic use of RWE and policy modeling enabled the company to secure favorable access positions across multiple geographies. In this role, Arup also led successful business development and licensing (BD&L) initiatives that positioned Indivior for long-term growth, reinforcing his reputation as both a strategic operator and visionary collaborator.
Returning to Boehringer Ingelheim in 2020, Arup took on the role of Vice President, Global Head of Market Access for Inflammation and Rare Diseases. He swiftly led a transformation in access and pricing strategies, driving the adoption of digital platforms for evidence generation, patient mapping, and payer engagement. His approach fused clinical excellence with cutting-edge analytics, enabling faster, more equitable access to life-altering therapies. His leadership not only grew revenue but also expanded Boehringer’s global market footprint, particularly in emerging economies and low-to-middle income countries.
A defining aspect of Arup’s leadership is his capacity to empower teams and build enduring institutional capability. Across multiple companies, he has designed and implemented comprehensive upskilling frameworks, enabling market access professionals to navigate increasingly complex pricing and regulatory environments. His ability to embed a “value-first” mindset across organizations has led to stronger payer relationships, higher launch success rates, and more robust internal cultures of innovation.
Arup’s influence extends beyond the boardroom into academia and policy. As an External Advisory Board Member at the Boston University School of Public Health, he contributes to shaping the next generation of health law and policy leaders. He is also a fellow of both the Royal College of Physicians, Ireland (MFOM), and the College of General Medicine, India (FCGP). These affiliations reflect his intellectual curiosity and lifelong commitment to advancing healthcare through multidisciplinary collaboration.
Throughout his career, Arup has remained deeply committed to global health equity. His extensive international experience includes operational leadership across the U.S., EU5, Japan, China, and beyond. Fluent in Bengali, Hindi, English, and conversational Malay, he bridges cultural and linguistic divides with ease—bringing rare global fluency to every initiative. Whether working with government health agencies, venture-backed startups, or multinational boards, Arup brings the same clarity of vision and purpose: ensuring that innovation reaches those who need it most.
Looking ahead, Arup is actively seeking board roles with biotech, medtech, and AI-health ventures—particularly those at the inflection point of scale. He is especially well-suited for companies aiming to translate complex science into commercial value, expand internationally, or navigate cross-border market access challenges. As he prepares to relocate to the U.S. in early 2026, Arup brings with him a legacy of strategic excellence, a vast global network, and a deep passion for patient-centered innovation.
Character:
Arup Pramanik exemplifies character through his consistent commitment to improving patient outcomes globally, regardless of region or socioeconomic status. His passion for ethical leadership and equity in healthcare has driven transformative partnerships across diverse geographies and stakeholders.
Knowledge:
With over two decades of experience across leading pharmaceutical organizations, Arup brings unmatched depth in market access, health economics, and AI-enabled commercialization. He fuses scientific rigor with business intelligence to unlock value in even the most challenging healthcare environments.
Strategic:
Arup has a proven ability to anticipate market shifts and align cross-functional teams to seize high-impact opportunities. His strategic insight has propelled the growth of billion-dollar portfolios and empowered companies to expand with speed and purpose.
Communication:
Fluent in multiple languages and deeply attuned to cross-cultural dynamics, Arup is a master communicator who bridges global teams and external stakeholders alike. His thought leadership, mentoring, and public speaking reflect a natural ability to articulate complex concepts with clarity and impact.
